Application Data
Vedolizumab (Entyvio) ELISA Kit
Vedolizumab (Entyvio)(mAb-based) ELISA Kit
Synonyms
Vedolizumab (Entyvio); N/A; Vedolizumab (Entyvio)(mAb-based) ELISA Kit; Vedolizumab (Entyvio) elisa kit
Application Data
Application Data
Related Product Information for Vedolizumab (Entyvio) elisa kit
ImmunoGuide Enzyme immunoassay (ELISA) for the specific determination of free Vedolizumab in serum and plasma.
The drug Vedolizumab (trade name Entyvio) is a humanized immunoglobulin G1 monoclonal antibody that binds exclusively to the lymphocyte integrin alpha4beta7, is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis [UC] or Crohn’s disease [CD]. According to the prescribing information, the mean ± SD of Vedolizumab steady-state trough serum concentrations in patients with UC and CD are reported to be 11.2±7.2 µg/mL (n=77) and 13.0±9.1 µg/mL (n=72) respectively. It was also reported in an other study that higher Vedolizumab trough concentrations were associated with greater efficacy in patients with both UC and CD. Higher Vedolizumab trough concentrations also were associated with numerically higher rates of clinical response and mucosal healing at week 6 in patients with UC. As with all therapeutic proteins, there is a potential for immunogenicity. According to the prescribing information, in patients who received Vedolizumab, the frequency of antibodies detected in patients was 13% at 24 weeks after the last dose of study drug. During treatment, 56 of 1434 (4%) of patients treated with Vedolizumab had detectable anti-Vedolizumab antibodies at any time during the 52 weeks of continuous treatment. Nine of 56 patients were persistently positive for anti-Vedolizumab antibodies and 33 of 56 patients developed neutralizing antibodies to Vedolizumab. The presence of persistent anti-Vedolizumab antibodies was observed to substantially reduce serum concentrations of Vedolizumab, either to undetectable or negligible levels at weeks 6 and 52.
Identification of biomarkers might be beneficial for (non-) response and risk factors for adverse drug reactions that might be related to serum drug levels and maintaining the effective concentration in order to potentially avoid some side effects with a reliable method. For research use only, not for use in test procedures.
The drug Vedolizumab (trade name Entyvio) is a humanized immunoglobulin G1 monoclonal antibody that binds exclusively to the lymphocyte integrin alpha4beta7, is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis [UC] or Crohn’s disease [CD]. According to the prescribing information, the mean ± SD of Vedolizumab steady-state trough serum concentrations in patients with UC and CD are reported to be 11.2±7.2 µg/mL (n=77) and 13.0±9.1 µg/mL (n=72) respectively. It was also reported in an other study that higher Vedolizumab trough concentrations were associated with greater efficacy in patients with both UC and CD. Higher Vedolizumab trough concentrations also were associated with numerically higher rates of clinical response and mucosal healing at week 6 in patients with UC. As with all therapeutic proteins, there is a potential for immunogenicity. According to the prescribing information, in patients who received Vedolizumab, the frequency of antibodies detected in patients was 13% at 24 weeks after the last dose of study drug. During treatment, 56 of 1434 (4%) of patients treated with Vedolizumab had detectable anti-Vedolizumab antibodies at any time during the 52 weeks of continuous treatment. Nine of 56 patients were persistently positive for anti-Vedolizumab antibodies and 33 of 56 patients developed neutralizing antibodies to Vedolizumab. The presence of persistent anti-Vedolizumab antibodies was observed to substantially reduce serum concentrations of Vedolizumab, either to undetectable or negligible levels at weeks 6 and 52.
Identification of biomarkers might be beneficial for (non-) response and risk factors for adverse drug reactions that might be related to serum drug levels and maintaining the effective concentration in order to potentially avoid some side effects with a reliable method. For research use only, not for use in test procedures.
Product Categories/Family for Vedolizumab (Entyvio) elisa kit
Similar Products
Product Notes
The Vedolizumab (Entyvio) (Catalog #AAA72735) is an ELISA Kit and is intended for research purposes only. The product is available for immediate purchase. It is sometimes possible for the material contained within the vial of "Vedolizumab (Entyvio), ELISA Kit" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.